The United States Congress and more than 28 state legislatures have considered spending billions of taxpayer dollars on stem cell research over the next several years. The National Institutes of Health has already committed billions. And in 2004, California voters approved the Stem Cell Research and Cures Initiative, also known as the Proposition 71 bond measure, which authorized the state to raise $3 billion over 10 years to fund such research.
Introduction
The United States Congress and more than 28 state legislatures have considered spending billions of taxpayer dollars on stem cell research over the next few years. The National Institutes of Health (NIH) has already committed billions. Though debates rage over the ethics of the work, a more fundamental question is being ignored: Is stem cell research a sensible expenditure of taxpayer dollars? This is not a question of whether the research should be conducted, but whether public funding for it is justified.
Because stem cell research is inherently speculative and politically controversial, the public would be best served if governments left it to the private sector. Politicians who promise cures in the near future for cancer and Parkinson's disease, lower future health care costs, and a booming biotechnology economy are being disingenuous. Each stem cell project is highly speculative, and it is not the place of government to gamble with taxpayers' money.
Furthermore, there is little risk that stem cell research will go unfunded-biotech companies, philanthropic organizations, and individuals have already invested billions of dollars in such research, and they show no sign of stopping. More importantly, the politicized nature of public debates over stem cell research threaten to spill over into and disrupt the research itself. The prospect of public funding so angers some Americans that it has spurred movements to restrict private stem cell research efforts. Under such circumstances, government funding for stem cell research is more hindrance than help to the advancement of science.
The Political Controversy
In November 2007, New Jersey voters rejected an initiative to borrow $450 million to fund state-run stem cell research. Defeat should not have come as a surprise. New Jersey voters had the advantage of seeing how little California's 2004 stem cell funding initiative has accomplished at an extremely high cost. New Jerseyites have also seen the flourishing of private stem cell research efforts in their own backyard, evidence that such research need not depend on government funding. Moreover, it simply makes no sense for a state with the highest per-capita public debt in the nation to borrow still more money to spend on stem cell research. 1 Yet some New Jersey legislators remain eager to increase taxes and spending to finance stem cell research-and they are not alone. By the end of 2008, the National Institutes of Health will have spent over $2.5 billion on stem cell research in just five years. Nine states, including California, New York, and Connecticut, have committed to combined spending of over $4.1 billion over the next 10 years. 2 Government funding advocates consistently downplay the significant financial risks involved in the research and the inefficiency of public programs in managing its progress.
They also seem to ignore the fact that private companies are doing just fine conducting stem cell research without government help or interference.
New Jersey voters were wise to learn from California's mistakes, and residents of others states would be wise to follow suit. Most of the problems that arose in California are endemic to government-run efforts in general, such as wasted time and money and political squabbling over the fair distribution of funds. This is not to suggest that private initiatives cannot be wasteful, inefficient, or unsuccessful-many biotechnology firms fail because they are high-risk ventures. diabetes, advanced kidney cancer, and spinal injury. 5 Cord blood stem cell transplants are used in therapies for leukemias and lymphomas. 6 And, in at least one experiment in mice, the onset of a form of Tay reach the market and patients more quickly by allowing scientists to target specific cells during drug testing. 19 In the long run, such advances could prevent or treat long-term illnesses, and thereby reduce the costs of certain treatments, but those results are highly uncertain. Even in the best of circumstances, effective therapies developed from embryonic stem cell research are decades away.
The National Academy of Sciences (NAS) has noted the elusive nature of the claimed benefits of stem cell research. As NAS researchers
explain, "what tend to be 'over-promised' are not only the potential outcomes of both embryonic and adult stem cell research, but also the time scales that are involved." Research leading to the development of feasible therapies can take years or even decades. And, once the therapeutic applications are developed, those applications need to be tested to show that they are safe, which adds additional years to the development of viable treatment options. 20 It is worth noting that the lag time in the pharmaceutical industry between the funding of basic research and a new drug product reaching the market is an estimated average of 18 years. 21 A stem cell therapy might take a shorter time to develop and test than a new drug, but it could just as easily take longer.
Given these realities, the campaign for passage of Proposition California taxpayers have devoted to stem cell research will save lives.
It is Misleading to Promise Reduced Health Care Costs
Promoters of the California initiative went beyond unrealistic medical promises. Advocates of Proposition 71 also argued that the massive stem cell spending would bring about certain financial gains. They told voters that Proposition 71 would "protect and benefit the California budget" by "funding scientific medical research that will significantly reduce state health care costs in the future" and provide "an opportunity for the state of licensing and royalty agreements remains unresolved. 30 Some legislators believe that CIRM's proposed royalty and licensing fees are too low to generate the promised revenue, while CIRM argues that any higher demands will scare away potential research and development partners, causing them to seek funds and development agreements elsewhere. 31 The inevitable compromise will make Proposition 71's promises of future royalties and more affordable health care tenuous at best.
Promises of potential royalties also fail to account for the challenges associated with the unresolved issue of patenting human embryonic stem cell technologies. The issues involved are at the cutting edge of intellectual property law, and the legal status of patents for stem cell lines and related products has been in flux for almost a decade.
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Because the patentability of stem cell technologies remains legally uncertain, potential stem cell research revenues are entirely hypothetical. 33 In this regard, James Thomson's discovery is important legally, as well as scientifically. He filed a patent application in 1998 before publishing his discovery of the unspecialized and self-renewing nature of embryonic stem cells. 34 The resulting patents granted were so broad that 
It Is Disingenuous to Promise Economic Growth
In addition to exaggerating the direct revenue gains from the initiative; 2006, lawmakers unsuccessfully tried to pass legislation to make CIRM's activities more transparent. 38 The political nature of government funding just means more delays to the already lengthy research process and makes financial returns on taxpayer dollars even more doubtful.
In needed to cover the debts incurred to pay for the research. Taxpayers will then have to ante up still more money to prevent research programs from closing down. Lowering taxes and reducing regulatory burdens in ways that would encourage private research institutions to move to California would be a better way to stimulate the economy than spending more tax money the state does not have.
Leadership. . . in Spending
Most state statutes funding stem cell research declare a legislative intent to propel the state to the forefront of research. Eleven states have initiated funding for stem cell research programs, and 28 have considered some form of such funding. Unfortunately, state action is more likely to hinder cutting-edge biotechnology research than it is to produce important scientific or medical breakthroughs.
Promises of World Leadership
Proposition 71 was promoted as a measure that would "advance the biotech industry in California to world leadership, as an economic engine for California's future. 45 There is little to suggest that government-run research programs could offer a better track record, and good reason to believe they would be worse.
Hindering, not Fostering, Research
State policy makers say they want their states to lead the world in stem cell 
There is a Better Way
Given the risks and questionable benefits, why are state governments rushing to fund stem cell research? Some argue that, precisely because of the risky nature of the work, private companies will either not pursue it or will only focus on the more immediately profitable aspects. These claims are false. The riskiness of cutting-edge research methods and technologies is standard in the biotechnology industry and is therefore unlikely to intimidate investors whose financing of the biotech industry totaled over $20 billion in 2005. 51 The more pressing risks hindering greater private investment are political controversy and the threat of stifling regulation.
Private funding continues to be vital to stem cell research. In fact, the most important breakthrough in the field, James Thomson's discovery of the nature of human embryonic stem cells, was the result of privately funded research. 52 And Thomson's discovery utilized embryos derived from in vitro fertilization (IVF) clinics, another private funding success story.
A Historical Success Story
To understand the possibilities of private research funding, an actual 
Private Funding is Versatile
Opponents of reliance on private-sector funding for research fail to recognize that private financing can come from multiple sources, for multiple motivations, and be intended to pursue multiple goals. For one, 
More Is Not Necessarily Better
Some proponents of government funding of stem cell research argue that more is better, and that there is no reason not to pursue both federal and private funding simultaneously. However, there is evidence that government spending "crowds out" private contributors. The
Congressional Budget Office (CBO) made exactly this point in a report on research and development in the pharmaceutical industry. "Even as it produces substantial social benefits," the CBO observed, government spending "on basic research and development can also discourage private 68 There are many more examples of a bourgeoning stem cell research market. A sampling of private companies working on stem cell research (see Table 2 ) clearly shows that, contrary to some government funding proponents' claims, private companies are investing heavily in stem cell research. debates can take place without getting bogged down in political struggles over whether or not it is appropriate for government to provide financial support for the research. A free market of ideas, with a plurality of private funding sources, in the long run will result in less waste and more funds being directed to those most vested in solving shared research concerns. 
Conclusion
While political squabbles continue to stymie public funding for stem cell research, enterprising private companies, foundations, and individuals have invested or donated funds, not only for general stem cell research, but also for testing potential therapies and related products. With the private sector taking such great strides, it is futile and self-defeating to go through tortuous efforts to secure government funding. Government programs, such as California's Proposition 71, are bureaucratic, wasteful, and mired in political controversy. As a result, the percentage of funds spent on actual research is low. Besides being wasteful, government programs can deter progress in the private sector.
Unnecessary and often onerous legislation and regulations impede the work of stem cell researchers and only add years to an already lengthy therapeutic development process.
Experience shows that it is possible to retain America's dominance in biotechnology without government funding, and current research continues to prove that private funding produces results more efficiently and effectively. No matter how much public funding proponents promise, the best way to make progress in stem cell research is to allow the private sector to grow, unimpeded by cumbersome regulation and political controversy.
